The etiology of community-acquired pneumonia at an urban public hospital: Influence of human immunodeficiency virus infection and initial severity of illness

Journal of Infectious Diseases

Volumn 184, Issue 3, 2001, Pages 268-277

  Park, David R ^a   Sherbin, Vandy L ^a,c,d   Goodman, Michelle S ^b   Pacifico, Albert D ^b,c,d   Rubenfeld, Gordon D ^a   Polissar, Nayak L ^a   Root, Richard K ^b  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^d Western Washington Medical Group   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADULT; AGED; ARTICLE; ASPIRATION; BACTERIAL INFECTION; COMMUNICABLE DISEASE; DISEASE SEVERITY; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LEGIONELLA; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIUM TUBERCULOSIS; MYCOPLASMA PNEUMONIAE; NONHUMAN; PNEUMOCYSTIS CARINII; PNEUMONIA; PRIORITY JOURNAL; PUBLIC HOSPITAL; RISK FACTOR; STREPTOCOCCUS PNEUMONIAE; URBAN AREA;

ADULT; AGED; AGED, 80 AND OVER; ALCOHOLISM; BLOOD TRANSFUSION; COCAINE-RELATED DISORDERS; COMMUNITY-ACQUIRED INFECTIONS; COMORBIDITY; FEMALE; HIV INFECTIONS; HIV SERONEGATIVITY; HOSPITALS, PUBLIC; HOSPITALS, URBAN; HUMANS; LEGIONELLOSIS; MALE; MARIJUANA ABUSE; MIDDLE AGED; MYCOBACTERIUM INFECTIONS; PNEUMONIA, BACTERIAL; PNEUMONIA, MYCOPLASMA; PNEUMONIA, PNEUMOCOCCAL; RISK FACTORS; SMOKING; SOCIOECONOMIC FACTORS; SUBSTANCE ABUSE, INTRAVENOUS; TUBERCULOSIS, PULMONARY; WASHINGTON;

EID: 0035425956     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/322040     Document Type: Article

References (59)

1. Epidemiology of community-acquired respiratory tract infections in adults: Incidence, etiology, and impact
2. Premature deaths, monthly mortality, and monthly physician contacts: United States
3. The cost of treating community-acquired pneumonia
4. Community-acquired pneumonia
5. Incidence of community-acquired pneumonia requiring hospitalization: Results of a population-based active surveillance study in Ohio
6. Empirical therapy of community-acquired pneumonia
7. An overview of community acquired pneumonia with lessons learned from the British Thoracic Society Study
8. Management of adult community-acquired lower respiratory tract infections
9. Guidelines for the initial management of adults with community-acquired pneumonia: Diagnosis, assessment of severity, and initial antimicrobial therapy
10. Community-acquired pneumonia in adults: Guidelines for management
11. Guidelines for management of adult community- acquired lower respiratory tract infections
12. Practice guidelines for the management of community-acquired pneumonia in adults
13. Use of guidelines in treating community-acquired pneumonia
14. New and emerging etiologies for community-acquired pneumonia with implications for therapy: A prospective multicenter study of 359 cases
15. Community-acquired pneumonia: Impact of immune status
16. Microscopic and bacteriologic analysis of expectorated sputum
17. Revised classification system for HIV infection and expanded surveillance case definition for AIDS among adolescents and adults
18. Prevalence of legionellosis among adults: A study of community-acquired pneumonia in France
19. Aetiology of community acquired pneumonia in Valencia, Spain: A multicentre prospective study
20. Aetiology of community-acquired pneumonia: A prospective study among adults requiring admission to hospital
21. Legionella pneumophila: A cause of severe community-acquired pneumonia
22. Etiology of community-acquired pneumonia in hospitalized patients: A 3-year prospective study in Japan
23. Multiple pathogens in adult patients admitted with community-acquired pneumonia: A one-year prospective study of 346 consecutive patients
24. Community-acquired pneumonia requiring hospitalization: 5-year prospective study
25. Community-acquired pneumonia in adults in British hospitals in 1982-1983: A survey of aetiology, mortality, prognostic factors, and outcome
26. Community acquired pneumonia: Aetiology and usefulness of severity criteria on admission
27. Aetiology, outcome and prognostic factors in community-acquired pneumonia requiring hospitalization
28. Etiology of community-acquired pneumonia: Impact of age. Comorbidity, and severity
29. Microbial aetiology of community-acquired pneumonia in hospitalised patients
30. Prospective study of community-acquired pneumonia of bacterial etiology in adults
31. Chlamydia pneumomiae as a cause of community-acquired pneumonia in hospitalized patients in Berlin
32. Community-acquired pneumonia: Etiology, epidemiology, and outcome at a teaching hospital in Argentina
33. Prospective study of the usefulness of sputum Gram stain in the initial approach to community-acquired pneumonia requiring hospitalization
34. Study of community acquired pneumonia aetiology (SCAPA) in adults admitted to hospital: Implications for management guidelines
35. Processes and outcomes of care for patients with community-acquired pneumonia: Results from the Pneumonia Patient Outcomes Research Team (PORT) cohort study
36. Bacterial pneumonia in HIV-infected patients: A prospective study of 68 episodes
37. Community acquired pneumonia in adults in Addis Ababa: Etiologic agents and the impact of HIV infection
38. Bacterial pneumonia in persons infected with the human immunodeficiency virus
39. Community-acquired pneumonia in a cohort of former injection drug users with and without human immunodeficiency virus infection: Incidence, etiologies, and clinical aspects
40. Acute community-acquired bacterial pneumonia in human immunodeficiency virus (HIV) infected and non-HIV-infected adult patients in Cameroon: Aetiology and outcome
41. Pyogenic bacterial pneumonia in human immunodeficiency virus-infected inpatients: A clinical, radiological, microbiological, and epidemiological study
42. Community-acquired bacterial pneumonia in human immunodeficiency virus-infected patients: Validation of severity criteria
43. Bacterial pneumonia in hospitalized patients with HIV infection: The Pulmonary Complications, ICU Support, and Prognostic Factors of Hospitalized Patients with HIV (PIP) Study
44. Pneumococcal disease during HIV infection: Epidemiologic, clinical, and immunologic perspectives
45. Respiratory disease trends in the Pulmonary Complications of HIV Infection Study cohort
46. Atypical pathogens in community-acquired pneumonia
47. Surveillance for Legionnaires' disease. Risk factors for morbidity and mortality
48. Legionellosis in a bone marrow transplant center
49. Community-acquired pneumonia: Importance of initial noninvasive bacteriologic and radiographic investigations
50. Cytomegalovirus pneumonia
51. Nontuberculous mycobacteria in patients with human immunodeficiency virus infection
52. Severe community-acquired pneumonia: Etiology, epidemiology, and prognosis factors
53. The aetiology of severe community-acquired pneumonia and its impact on initial, empiric, antimicrobial chemotherapy
54. Severe community-acquired pneumonia: Risk factors and follow-up epidemiology
55. Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia
56. Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia
57. A controlled trial of a critical pathway for treatment of community-acquired pneumonia. Community-Acquired Pneumonia Intervention Trial Assessing Levofloxacin
58. Implications for macrolide treatment in community-acquired pneumonia
59. Effect of highly active antiretroviral therapy on the incidence of bacterial pneumonia in HIV-infected subjects